Logistic regression analysis of influencing factors of adverse drug reaction of glimepiride and their effect on treatment of T2DM

doi:10.19803/j.1672-8629.2022.09.21

Abstract

Abstract: Objective To analyze the influencing factors of adverse drug reaction (ADR) of glimepiride and their effect on the efficacy of treatment of type 2 diabetes mellitus (T2DM). Methods From June 1, 2018 to June 30, 2020, 123 patients with T2DM admitted to our hospital were prospectively selected and treated with glimepiride. The incidence of ADR was recorded, and these patients were divided into the ADR group and non-ADR group according to the presence or absence of ADR. The baseline data, blood glucose levels [fasting blood glucose (FBG), 2 h postprandial blood glucose (2hBG), hemoglobin A1c (HbA1c)], pancreatic β cell function [homeostasis model assessment of insulin resistance (HOMA-IR), homeostasis model assessment for β-cell function (HOMA-β)] and blood lipids [triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C)] were compared between the two groups. Factors affecting the ADR of glimepiride were analyzed, and the efficacy of treatment was compared between the two groups. Results After the 123 patients with T2DM were treated with glimepiride, ADR occurred in 29 of them (23.58%). Age over 70, alcohol consumption, off-label medications, single doses of 2~4 mg, lack of compliance, and long medication were independent risk factors for ADR of glimepiride (P<0.05). The total effective rate of the ADR group was 72.41% (21/29), which was lower than 92.55% (87/94) in the non-ADR group (P<0.05). Conclusion The risk of ADR associated with glimepiride is high among those who are over 70 years old, drink alcohol, take large single doses, and take this drug for a long time. Such measures such as improving compliance and strengthening the supervision of indications can help reduce the ADR of glimepiride.

Key words: glimepiride, adverse drug reaction, type 2 diabetes mellitus, single dose, effectiveness

CLC Number:

R994.11

YANG Liu, SHI Fenghua, MA Lijuian. Logistic regression analysis of influencing factors of adverse drug reaction of glimepiride and their effect on treatment of T2DM[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1030-1034.

References

[1] FU P.Association of dyslipidemia with the development and progression of type 2 diabetes[J]. Journal of Luzhou Medical College(西南医科大学学报), 2018,4(3):287-290
[2] RIDDERSTRÅLE M, ROSENSTOCK J, ANDERSEN KR, et al. Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial[J].Diabetes Obes Metab, 2018, 20(12): 2768-2777.
[3] MÜLLER-WIELAND D, KELLERER M, CYPRYK K, et al.Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes[J]. Diabetes Obes Metab, 2018, 20(11): 2598-2607.
[4] QIAN D, TAN XP, MEI ZR, et al.Efficacy and safety of dipeptidyl peptidase-4 inhibitors combined with sulfonylureas in type 2 diabetes mellitus :a Meta-analysis[J]. Chongqing Medicine(重庆医学), 2019, 48(16): 2814-2821.
[5] YE LH, HE M, ZHAO XQ, et al.Research progress of potential drug interactions of sulfonylureas[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2018, 38(12): 1333-1337.
[6] MOKTA JK, RAMESH, SAHAI AK, et al.Comparison of safety and efficacy of glimepiride-metformin and vildagliptin- metformin treatment in newly diagnosed type 2 diabetic patients[J]. J Assoc Physicians India, 2018, 66(8): 30-35.
[7] HOLLANDER P, HILL J, Johnson J, et al.Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin[J]. Curr Med Res Opin, 2019, 35(8): 1335-1343.
[8] GAO JR, LI Y, LUO H, et al.Analysis of adverse reactions/events of glimepiride based on case reports[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2015, 35(13): 1231-1233.
[9] BAJAJ S.RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017[J]. Int J Diabetes Dev Ctries, 2018, 38(Suppl 1): 1-115.
[10] National Center for ADR Monitoring,China. Technical specifications and evaluation criteria of common severe adverse drug reactions(常见严重药品不良反应技术规范及评价标准)[S]. 2011.
[11] WANG YM, WANG GJ, ZHANG SL, et al.Adverse drug reactions of antidiabetic drugs and the preventive strategies[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2015, 35(24): 2233-2236.
[12] LI F, LIU ZG.Analysis report on 425 cases of adverse reactions of hypoglycemic drugs[J]. Shanxi Medical Journal(山西医药杂志), 2018, 47(14): 1715-1717.
[13] YI P.Analysis of adverse reactions of sulfonylureas and study on rational drug use[J]. Chinese Journal of Critical Care Medicine(中国急救医学),2017,37(z2):36-37.
[14] China food and drug administration.2015 national adverse drug reaction monitoring annual report(2015年国家药品不良反应监测年度报告)[EB/OL].(2016-07-13)[2019-12-30].https://www.doc88.com/p-2485232561901.html.
[15] SHU B, LIU YL, Jiang L.Research progress of evaluation criteria for potential inappropriate drug use in the elderly[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2019, 39(18): 1905-1910.
[16] ZHANG XL, ZHOU S, ZHOU Y, et al.Research progress in inappropriate drug use in the elderly[J]. Chinese Journal of Geriatrics(中华老年医学杂志), 2018, 37(4): 479-484.
[17] KONG YX, DONG AM, ZHENG JT, et al.Hypoglycemia and its influential factors in outpatients with type 2 diabetes mellitus[J].Chinese General Practice(中国全科医学), 2019, 2(8): 936-941.
[18] CHEN CM, WANG G.Exploring the influence of extrapancreatic effect of sulphonylureas on clinical outcomes in patients with type 2 diabetes[J]. Chinese Journal of Endocrinology and Metabolism(中华内分泌代谢杂志), 2019, 35(1): 76-80.
[19] TERAUCHI Y, YAMADA Y, ISHIDA H, et al.Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START-J trial)[J].Diabetes Obes Metab, 2017, 19(8): 1188-1192.
[20] BIESSELS GJ, JANSSEN J, VAN DEN BERG E, et al. Rationale and design of the CAROLINA® - cognition substudy:a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus[J]. BMC Neurol, 2018, 18(1): 7.